Physiomics awarded further contract by Numab Therapeutics

Data science company Physiomics said on Monday that it had been awarded a further contract by an existing client.

Physiomics said Numab Therapeutics had tapped it to work on a project that involves Pharmacokinetic-Pharmacodynamic modelling in support of one of Numab's oncology assets entering the clinic and will help inform dose and scheduling decisions.

Chief executive Peter Sargent said: "We are thrilled to have this opportunity to continue working with and supporting Numab on this asset through its preclinical stages as it heads into the clinic.

"Along with the project we announced with them in August 2023, this new project is a testament to the continued support we provide and the great relationships we've built".

As of 1415 GMT, Physiomics shares were up 8.28% at 1.57p.

Reporting by Iain Gilbert at Sharecast.com